Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aytu Biopharma (AYTU) Finished Goods: 2019-2025

Historic Finished Goods for Aytu Biopharma (AYTU) over the last 7 years, with Jun 2025 value amounting to $8.9 million.

  • Aytu Biopharma's Finished Goods rose 2.74% to $7.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $7.9 million, marking a year-over-year increase of 2.74%. This contributed to the annual value of $8.9 million for FY2025, which is 45.33% up from last year.
  • According to the latest figures from FY2025, Aytu Biopharma's Finished Goods is $8.9 million, which was up 45.33% from $6.2 million recorded in FY2024.
  • In the past 5 years, Aytu Biopharma's Finished Goods ranged from a high of $10.7 million in FY2021 and a low of $6.2 million during FY2024.
  • In the last 3 years, Aytu Biopharma's Finished Goods had a median value of $7.7 million in 2023 and averaged $7.6 million.
  • In the last 5 years, Aytu Biopharma's Finished Goods plummeted by 32.89% in 2022 and then skyrocketed by 45.33% in 2025.
  • Yearly analysis of 5 years shows Aytu Biopharma's Finished Goods stood at $10.7 million in 2021, then slumped by 32.89% to $7.2 million in 2022, then climbed by 7.52% to $7.7 million in 2023, then dropped by 20.52% to $6.2 million in 2024, then surged by 45.33% to $8.9 million in 2025.